Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells

3 May 2019

Abstract excerpt

OBJECTIVES: Epigenetic modifiers were important players in the development of haematological malignancies and sensitivity to therapy. Mutations of SET domain-containing 2 (SETD2), a methyltransferase that catalyses the trimethylation of histone 3 on lysine 36 (H3K36me3), were found in various myeloid malignancies. However, the detailed mechanisms through which SETD2 confers chronic myeloid leukaemia progression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31054182
DOI: 10.1111/cpr.12611

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cellsPMID 31054182Read ↗

Roles of SETD2 in Leukemia—Transcription, DNA-Damage, and BeyondSemantic proximity Read ↗

Identification of functional cooperative mutations of SETD2 in human acute leukemia.Semantic proximity Read ↗

Discovery of a Non-Nucleoside SETD2 Methyltransferase Inhibitor against Acute Myeloid Leukemia.Semantic proximity Read ↗

SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.Semantic proximity Read ↗

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.Semantic proximity Read ↗

SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia.Semantic proximity Read ↗

The SETD2 L1609P mutation found in leukemia disrupts methyltransferase activity and reduces histone H3K36 trimethylation.Semantic proximity Read ↗

SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation.Semantic proximity Read ↗

SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDSSemantic proximity Read ↗

New insights into the clinical characteristics of SETD2-mutated acute myeloid leukaemia.Semantic proximity Read ↗

Loss of MBD2 attenuates MLL-AF9-driven leukemogenesis by suppressing the leukemic cell cycle via CDKN1CSemantic proximity Read ↗

[Research progress on the expression and carcinogenic mechanisms of SETD2 in malignant tumors].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.